Browse the evidence

YouTube videos on semaglutide (Ozempic/Wegovy) largely fail to adequately communicate critical safety risks, specifically the risk of aspiration during anesthesia, the persistence of side effects due to the drug's long half-life, the risk of counterfeit drugs, and the lack of long-term data.

Do not rely on YouTube videos for safety information about semaglutide. They often miss critical risks like aspiration during surgery, the persistence of side effects due to the drug's long half-life, and the danger of counterfeit products. Always consult a physician for personalized advice and safety monitoring.

In people with suppressed HIV and metabolic dysfunction-associated fatty liver disease (MAFLD), adjunctive treatment with maraviroc, metformin, or their combination for 48 weeks does not significantly reduce liver fat fraction compared to antiretroviral therapy alone.

If you have HIV and fatty liver, adding maraviroc or metformin to your standard HIV treatment is unlikely to reduce the fat in your liver. The trial showed no significant benefit for liver fat reduction compared to just staying on your HIV medication. Focus on proven lifestyle strategies for metabolic health.

Mitochondrial dysfunction, specifically the loss of mild depolarization in short-lived mice, contributes to aging by increasing ROS-mediated protein damage.

Maintaining mitochondrial health through exercise and healthy metabolism may preserve the 'mild depolarization' state seen in long-lived species, potentially reducing oxidative stress.

Non-coding RNAs (miRNAs, lncRNAs, circRNAs) regulate gene expression in metabolic diseases and serve as diagnostic/prognostic biomarkers and potential therapeutic targets.

Research into non-coding RNAs is leading to new diagnostic tools and potential drugs that can silence or enhance specific genes involved in metabolism, offering hope for treating conditions like obesity and diabetes.

Administration of insulin-sensitivity-associated bacteria, specifically Alistipes indistinctus, ameliorates insulin resistance and improves glucose tolerance in high-fat diet-fed mice by reducing caecal monosaccharide levels.

Specific gut bacteria, such as Alistipes indistinctus, can help break down harmful sugars in the gut, potentially improving insulin sensitivity. This suggests that targeting specific bacterial strains could be a therapeutic strategy for metabolic health.

Healthcare professionals should assess biochemical hyperandrogenism using validated tandem mass spectrometry (LC-MS/MS) for testosterone, avoiding direct immunoassays due to their limited accuracy.

When getting blood work for PCOS, ensure your doctor orders testosterone testing via 'tandem mass spectrometry' (LC-MS/MS). This is the gold standard for accuracy. Avoid standard immunoassays if possible.

Genetically predicted leisure television watching causally increases the risk of COVID-19 hospitalization and disease severity.

Reduce time spent watching television, as it is causally linked to higher risks of COVID-19 hospitalization and severity. This risk is mediated by metabolic factors like obesity and smoking, so replacing TV time with physical activity may mitigate these risks.

Vagal afferent signaling regarding food intake is primarily driven by mechanoreceptors (IGLEs) sensing intestinal stretch, rather than chemoreceptors sensing gut peptides like GLP-1.

When taking GLP-1 medications, part of the weight loss comes from the physical feeling of fullness (stretch) in your stomach and intestines, not just a chemical signal. This is why you feel full faster and stay full longer. The drug enhances these mechanical signals to your brain.

Depletion of Kupffer cells (liver macrophages) improves insulin signaling and hepatic insulin sensitivity in obese mice.

Targeting liver inflammation may be a viable strategy for improving insulin sensitivity, though current clinical applications of macrophage depletion are limited.

Exenatide treatment significantly reduces dopamine transporter (DAT) availability in the striatum, caudate, and putamen in patients with Alcohol Use Disorder.

Exenatide changes the brain's dopamine transporter levels in key reward areas, which may help compensate for the dopamine deficits seen in chronic alcohol use. This is a biological mechanism, not a direct measure of drinking behavior.

Epigenetic aging initiates early in life upon the loss of pluripotency during differentiation, and the epigenetic age of a tissue is largely determined by the composition of stem cells versus differentiated cells.

Epigenetic aging begins when cells lose their stem-like pluripotency and start differentiating. The overall epigenetic age of a tissue reflects the balance of young stem cells and older differentiated cells. Maintaining a healthy stem cell pool may help keep tissue-level epigenetic age lower.

Prophylactic administration of uPAR-targeting CAR T cells in young mice prevents the development of age-related metabolic dysfunction and maintains exercise capacity into old age.

Treating young organisms with senolytic CAR T cells can prevent metabolic decline and maintain physical fitness into old age. This suggests that early intervention might be more effective than late-stage treatment.

Combining Endoscopic Gastric Remodeling (EGR) with a GLP-1 Receptor Agonist (GLP-1RA) initiated within 6 months of the procedure yields significantly greater weight loss (23.7% TWL) than EGR monotherapy or sequential therapy.

If you are considering Endoscopic Gastric Remodeling (EGR), ask about starting a GLP-1RA (like semaglutide or liraglutide) within 6 months of the procedure. This specific combination yields significantly better weight loss (approx. 24%) than either treatment alone. Avoid taking other types of weight loss medications for more than 6 months before the procedure, as this is associated with poorer outcomes.

Anti-obesity medication (AOM) administered in primary care settings produces approximately double the weight loss compared to lifestyle interventions alone, achieving an additional ~3 kg reduction.

If you are working with a primary care provider to lose weight, adding an FDA-approved anti-obesity medication to your lifestyle plan can roughly double your weight loss results compared to lifestyle changes alone. However, be prepared for the possibility that you may need to stay on the medication long-term to maintain the loss, as weight regain is common when stopping treatment.

Adjunctive semaglutide therapy significantly enhances total body weight loss and prevents post-balloon weight regain compared to intragastric balloon (IGB) alone in patients with BMI ≥ 27 kg/m².

If you are using an intragastric balloon for weight loss, adding semaglutide (a GLP-1 medication) can significantly increase your total weight loss and help you keep the weight off after the balloon is removed. The study used a specific dosing schedule starting at 0.5mg and going up to 1mg weekly, pausing while the balloon is in place, and restarting after removal. This approach helps overcome the natural weight regain that often happens after balloon removal alone.

High-intensity interval exercise (HIIE) or resistance training can mitigate the negative effects of sleep restriction on muscle protein synthesis, preserving synthesis rates despite sleep loss.

If you know you will have a night of poor sleep, do not skip your workout. High-intensity interval training or resistance exercise can help protect your muscle protein synthesis rates. Think of exercise as a buffer against the negative effects of sleep loss.

A 12-week periodic ketogenic diet (30-50g carbs, 130g fat, 60g protein, ~1500 kcal) significantly improves body weight, BMI, waist circumference, fasting blood glucose, fasting insulin, HbA1c, and lipid profiles (TG, TC, LDL) in newly diagnosed overweight/obese T2DM patients compared to routine diabetes diet.

If you are newly diagnosed with Type 2 Diabetes and overweight, a 12-week ketogenic diet (approx. 1500 calories, very low carb) can significantly improve your weight, blood sugar, and cholesterol better than standard diabetes advice. However, it is difficult to sustain long-term due to taste and adherence issues. It serves as an effective short-term intervention to reduce medication needs and improve metabolic health.

Adopting vegetarian or vegan diets significantly improves cardiometabolic risk factors, including lower total cholesterol, LDL cholesterol, blood pressure, BMI, and fasting glucose, compared to omnivorous diets.

To improve heart health and metabolic markers, shift your diet towards plant-based sources (vegetables, fruits, legumes, whole grains) and reduce or eliminate animal products. Expect improvements in cholesterol, blood pressure, and weight management, though you should monitor nutrient status, particularly B12.

Soy protein supplementation produces identical increases in lean mass compared to whey protein in active individuals and athletes, making it an effective alternative for muscle growth.

If you are an athlete or active individual looking to build muscle, soy protein is just as effective as whey protein. You do not need to avoid soy for muscle gains. Ensure you are consuming enough total protein (at least 1.6 g/kg/day) and that your soy protein source is of high quality (high digestibility).

Adherence to a healthful plant-based diet (hPDI) is associated with lower risk of obesity and less weight gain, whereas adherence to an unhealthful plant-based diet (uPDI) is associated with higher risk of obesity and more weight gain.

To manage weight, focus on the quality of your plant foods. Prioritize whole grains, fruits, vegetables, nuts, and legumes (healthful plant foods) while limiting refined grains and added sugars (unhealthful plant foods). Simply being vegetarian is not enough; the quality of the plants matters significantly for preventing obesity.

Pharmacologic management using GLP-1 receptor agonists (specifically liraglutide), topiramate, and phentermine/topiramate is effective for treating weight regain or weight loss plateaus following bariatric surgery.

If you are regaining weight after bariatric surgery, ask your provider about GLP-1 agonists (like liraglutide) or topiramate-based therapies. Current observational data supports their use for weight optimization in this specific population.

Adopting a healthful plant-based diet (high in whole grains, fruits, vegetables, nuts, legumes; low in refined grains, sweets, sugar-sweetened beverages, and animal foods) is associated with favorable health outcomes, including reduced risk of obesity, cardiovascular disease, diabetes, and mortality.

To improve your health, focus on the quality of your plant-based foods. Prioritize whole grains, fruits, vegetables, nuts, and legumes while minimizing refined grains, sweets, and sugar-sweetened beverages. You do not need to eliminate animal products entirely to see benefits; simply increasing the quality of plant foods in your diet is associated with lower risks of obesity, heart disease, diabetes, and mortality.

Combining beinaglutide (0.2 mg TID) with metformin (850 mg BID) produces significantly greater weight loss and improvements in insulin sensitivity and hyperandrogenism compared to metformin monotherapy in obese women with PCOS over a 12-week period.

For obese women with PCOS who are already taking metformin but struggling with weight loss or high androgens, adding beinaglutide (starting low and titrating up) is a clinically superior strategy to staying on metformin alone. This combination leads to significantly more weight loss, better waist circumference reduction, and improved insulin sensitivity. While it involves injections, the study found that side effects were manageable and did not cause more people to quit than those taking metformin alone. This approach is particularly relevant for those who have not achieved sufficient results with lifestyle changes and metformin monotherapy.

Lifestyle interventions, specifically combining dietary changes (low-calorie, low-fat, low-carbohydrate, high-protein, or low-glycemic-index diets) with exercise, are the first-line and fundamental treatment for obesity.

Start with lifestyle changes as your primary tool. Combine a calorie-controlled diet (whether low-fat, low-carb, or high-protein) with regular exercise (aim for 150 minutes of moderate activity or 75 minutes of vigorous activity per week, plus strength training twice a week). This combination is more effective than diet or exercise alone. Save medications and surgery for cases where lifestyle changes are insufficient or for severe obesity.